Objectives We sought to systematically evaluate the external validity of a contemporary randomized controlled stent trial (BIOSCIENCE). Methods Baseline characteristics and clinical outcomes of patients enrolled into the BIOSCIENCE trial at Bern University Hospital (n = 1216) were compared to those of patients included in the CARDIOBASE Bern PCI Registry at the same institution (n = 1045). The primary study endpoint was the rate of target lesion failure (TLF), defined as a composite of cardiac death, target vessel-myocardial infarction (MI) or target lesion revascularization (TLR), at 1 year. Results Women were underrepresented in the RCT compared to the registry (25 vs. 29.4 %, p = 0.020). Nonparticipants were older compared to study participants (69.2 ± 12.4 vs. 67.0 ± 11.6, p \ 0.001), and had a higher prevalence of previous cerebrovascular events (10.8 vs. 5.2 %, p \ 0.001), and chronic renal failure (35.5 vs. 15.6 %, p \ 0.001). ST-segment elevation myocardial infarction (STEMI) and Killip class IV at presentation were more common among non-participants than participants (30.7 vs. 21.1 %, p \ 0.001 and 7.8 vs. 0.4 %, p \ 0.001, respectively). At 1 year, non-participants experienced a significantly higher rate of TLF, (15.0 vs. 6.5 %, p \ 0.001), and patient-oriented composite endpoint (POCE), including death, MI or any repeat revascularization (21.6 vs. 11.2 %, p \ 0.001). There was a significant interaction between POCE and presence or absence of an acute coronary syndrome in participants versus non-participants, respectively (p = 0.009). Conclusions Non-participants of this all-comers trial had a higher risk profile and adverse prognosis compared to study participants. Further efforts are needed to improve the external validity of contemporary RCTs.
Drug-eluting stents (DES) represent the standard of care for percutaneous coronary revascularization [1] and transformed the field of interventional cardiology conferring higher efficacy as compared to bare-metal stents (BMS) [2] [3] [4] . Moreover, new generation DES featuring reduced strut thickness, ameliorated design, biocompatible polymers and reduced dosages of anti-proliferative drugs surpassed first generation DES in terms of efficacy and safety [5] .
Randomized controlled trials (RCTs) are the cornerstone of treatment recommendations and clinical guidelines. During the past decade, the evolution of stent technology was paralleled by the refinement of design and accuracy of randomized trials assessing their performance. Ensuring internal validity of RCTs by reducing the risk of chance, confounding and potential bias has been strongly recommended and adopted by a growing number of researchers [6] . The need to provide generalizable evidence prompted the design of trials with minimal exclusion criteria, generally referred to as all-comer design [7, 8] . However, the adequacy of contemporary interventional trials to reflect routine clinical practice outside of study protocols needs to be delineated. Indeed, inadequate consideration of issues affecting the external validity is one of the most common criticisms of RCTs [9] .
The BIOSCIENCE trial was a randomized controlled multicenter study showing non-inferiority of the biodegradable polymer-sirolimus eluting Orsiro stent (BP-SES) to the durable polymer-everolimus eluting Xience stent (DP-EES) in a population with minimal exclusion criteria [10] . The objective of the present analysis was to compare clinical features and outcomes of study participants at Bern University Hospital versus subjects undergoing percutaneous coronary intervention (PCI) at the same institution but not included in the trial.
Methods

Study population
The study population included participants of the BIOSCIENCE trial (NCT01443104) who were enrolled at the Bern university Hospital and non-participants included in the CARDIOBASE Bern PCI registry during the same study period (between February 2012 and May 2013).
The BIOSCIENCE was an investigator-initiated, multicenter, single-blind, randomized trial assessing the noninferiority of the Orsiro BP-SES (Biotronik AG, Bülach, Switzerland) relative to the Xience DP-EES (Abbott Vascular, Abbott Park, IL, USA) [11] .
Eligibility was defined by: age above 18 years, presence of stable coronary artery disease (CAD) or acute coronary syndromes (ACS), de novo or restenotic lesions in native coronary arteries or bypass grafts. Patients were excluded in case of pregnancy, inability to provide consent, participation in another trial, intolerance to aspirin, clopidogrel, or components of DES, and surgery planned within 6 months after the index PCI that would require discontinuation of dual antiplatelet therapy (DAPT) [10] . The CARDIOBASE Bern PCI Registry (NCT02241291) collects clinical, procedural and outcome data of patients undergoing PCI in the setting of stable CAD or ACS at Bern University Hospital. For the purpose of the present analysis, patients included in the registry during the enrollment time of the BIOSCIENCE trial were used. The trial and the registry were managed in accordance with the Declaration of Helsinki and patients provided written informed consent.
Procedures and follow-up
Participants of the BIOSCIENCE trial were randomly allocated in a 1:1 ratio to the treatment with BP-SES or DP-EES, respectively. Details of the study devices have previously been reported [10] . Clinical follow-up was performed at 30 days and 1 year after PCI. Regardless of patient allocation, PCI was performed according to international recommendations [1] . As for study protocol, all patients in the trial received new generation DES (BP-SES or DP-EES). Non-participants also received new generation DES in the vast majority of cases, including zotarolimus-eluting stents (Resolute, Medtronic Cardiovascular), biodegradable polymer DES (BioMatrix, Biosensors Europe; Synergy, Boston Scientific Corporation), and bioresorbable vascular scaffold (Absorb, Abbott Vascular). The Clinical Trials Unit and the Department of Cardiology at Bern University Hospital had the responsibility of data monitoring and storing for both the trial and the registry. Adverse events were adjudicated by a dedicated clinical events committee in both study participants and non-participants, respectively.
Study endpoints
The primary endpoint of this study was the rate of target lesion failure (TLF), defined as a composite of cardiac death, target vessel-myocardial infarction (MI) or target lesion revascularization (TLR), at 1 year. Secondary endpoints were a patient-oriented composite endpoint (POCE), including all-cause death, MI or any repeat revascularization; all-cause death; cardiac death; MI; repeat revascularization; and definite or probable stent thrombosis (ST). Definitions of study endpoints have been reported in detail elsewhere [10] . Briefly, cardiac death was considered as any death of immediate cardiac cause, death related to the procedure, unwitnessed death, and death of unknown cause. Myocardial infarction was defined as Q wave and non-Q wave according to the electrocardiographic criteria of the Minnesota code manual [12] . The definition of MI included: spontaneous MI, peri-procedural MI and reinfarction. TLR was considered as any repeat percutaneous or surgical intervention because of a stenosis within the stent or within the 5-mm borders proximal or distal to the stent. ST was defined on the basis of the Academic Research Consortium criteria [13] . A landmark analysis with a landmark set at 30 days to provide insights into the differences in early and late event rates through the different study cohorts was also performed. Stratified analyses were pre-defined: acute coronary syndrome, ST-elevation myocardial infarction, diabetes, gender, age C65 years, BMI C30 kg/m 2 , renal failure, multivessel treatment, in-stent restenosis (any lesion), long lesions (total stent length in any lesion [20 mm), small vessels (stent diameter in any lesion \3.0 mm), stent used (BP-SES only vs DP-EES only). We also re-analyzed the primary endpoint after excluding cardiogenic shock patients. A p value of \0.05 was considered significant, and all tests were 2-tailed. All analyses were carried out with Stata 14 (College Station, TX: StataCorp LP).
Results
Study population
Between February 2012 and May 2013, 2261 patients underwent PCI in our institution. 1216 patients participated in the BIOSCIENCE trial (57.3 % of the overall trial population); the remaining 1045 patients not participating in the trial were included into the CARDIOBASE Bern PCI Registry ( Fig. 1) . Baseline clinical characteristics Table 1 shows baseline clinical characteristics of participants in the BIOSCIENCE trial as compared to non-participants. Women were underrepresented in the RCT compared to the registry (25 vs. 29.4 %, p = 0.020). Patients included into the registry were older (69.2 ± 12.4 vs. 67.0 ± 11.6 years, p \ 0.001), and had a significantly higher prevalence of previous cerebrovascular events (10.8 vs. 5.2 %, p \ 0.001), and chronic renal failure (35.5 vs. 15.6 %, p \ 0.001).
Moreover, non-participants presented with lower left ventricular ejection fraction (51.2 ± 15.5 vs. 54.6 ± 12.3 %, p \ 0.001).
Conversely, a family history of CAD (25.9 vs. 18.0 %, p \ 0.001) and previous PCI (30.2 vs. 22.1 %, p \ 0.001) were more common among study participants.
Regarding clinical presentation, the registry included a significantly higher number of patients with ST-segment elevation myocardial infarction (STEMI) (30.7 vs. 21.1 %, p \ 0.001) and patients with Killip class IV at presentation (7.8 vs. 0.4 %) compared with patients included into the RCT. Study arms also differed with respect to medical treatment at baseline: patients in the trial were more likely to be on DAPT (20.1 % vs. registry 9.9 %, p \ 0.001), statins (54.3 vs. 46.3 %, p \ 0.001) and beta-blockers (48.6 vs. 42.0 %, p = 0.003). In contrast, oral anticoagulation (OAC) was more frequent among patients in the registry (8.4 vs. 12.9 %, p = 0.001). Similarly, at discharge, 98.1 versus 92.4 % of patients were on DAPT in the trial and registry, respectively (p \ 0.001); higher use of ticagrelor and statins was reported among patients included in the trial (Online Resource 1).
Procedural characteristics
Angiographic and procedural characteristics are summarized in Online Resource 2. There were no significant differences in the number of treated lesions and target vessel location between the two cohorts. In addition, the number of complex lesions was comparable between study participants and non-participants. As per study protocol, participants of the trial received BP-SES or DP-EES, and only three patients received bare-metal stents (BMS). The vast majority of subjects included in the registry were treated with DES, and only 5.9 % received BMS. Significantly higher use of intra-aortic balloon pump counterpulsation (2.9 vs. 0.3 %) and vasopressors (8.0 vs. 0.9 %) was reported in the registry compared to the RCT. Table 2 and Fig. 2 show clinical outcomes of participants relative to non-participants after 1 year from the index procedure.
Clinical outcomes
The rate of the primary endpoint, TLF, amounted to 6.5 % in the RCT versus 15.0 % in the registry, respectively (RR 0.40, 95 % CI 0.30-0.53, p \ 0.001).
The patient-oriented composite endpoint (POCE) occurred in 11.2 % of RCT compared to 21.6 % of registry patients (RR 0.47, 95 % CI 0.38-0.59, p \ 0.001).
RCT participants experienced significantly lower rates of all-cause death (3.1 vs. 14.1 %, RR 0.20, 95 % CI 0.14-0.29, p \ 0.001), cardiac death (2.0 vs. 10.5 %, RR 0.18, 95 % CI 0.11-0.28, p \ 0.001), MI (4.0 vs. 5.8 %, RR 0.66, 95 % CI 0.45-0.98, p = 0.038) and definite or probable ST (2.7 vs. 10.4 %, RR 0.25, 95 % CI 0.17-0.37, p \ 0.001) compared to registry participants. Rates of repeat revascularization (including target lesion and target vessel revascularization) were not significantly different between the two study cohorts (7.4 vs. 7.8 %, RR 0.92, 95 % CI 0.67-1.27, p = 0.614). The rate of POCE was not affected by the type of stent used, in both the registry and the trial (Online Resource 3).
In a landmark analysis of all-cause death, MI, repeat revascularization and POCE with the landmark set at 30 days, registry participants experienced significantly higher rates of adverse events compared to RCT participants within the first month after PCI (Fig. 3) . The difference in outcome was preserved up to 1 year for the rate of all-cause death and POCE, whereas a reversal of the trend for repeat revascularizations, disfavoring patients in the registry, was observed beyond 30 days. Moreover, after the first month, rates of MI did not significantly differ between the two cohorts. Figure 4 shows the risk of POCE among RCT versus registry patients across pre-specified subgroups. The lower risk of POCE in RCT patients was particularly pronounced among patients presenting with ACS (RR 0.38, 95 % CI 0.28-0.51) compared to patients presenting with stable coronary artery disease (RR 0.70, 95 % CI 0.49-0.99), with a statistically significant interaction for presence or absence of ACS (p = 0.009).
Discussion
The present analysis comparing all-comer study RCT participants with registry participants with regard to clinical characteristics, presentation and outcome recruited during the same time period at a single tertiary care center provided the following findings:
1. RCT participants were younger, more commonly male, and had a lower clinical risk profile as compared to registry participants; along the same line, patients presenting with STEMI and cardiogenic shock were underrepresented in the RCT.
Clin Data expressed as n (%) or means ± standard deviations ACE angiotensin converting enzyme, CABG coronary artery bypass grafting, CAD coronary artery disease, GFR glomerular filtration rate, MI myocardial infarction, NSTEMI non-ST segment elevation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, TIA transient ischemic attack 2. The risk of death, patient-oriented adverse events and ST was more than doubled in registry participants compared to RCT participants up to 1 year after PCI. While the effect on all-cause mortality was consistent within the first 30 days and beyond, the difference with regard to MI and repeat revascularization was limited to the first 30 days after intervention. 3. The difference in the risk of POCE between RCT participants and registry participants was accentuated in patients presenting with ACS.
RCTs are considered to generate the most reliable evidence, and provide the robust basis of treatment recommendations, expert consensus, and clinical guidelines. The use of new generation DES is currently recommended in all patient and lesion subsets among patients undergoing PCI, on the basis of head-to-head comparisons of different devices [1, [14] [15] [16] . The development of novel stent designs bearing the potential to refine the performance of new generation DES and scaffolds is paralleled by a progressive evolution of trial designs. Sample size calculations are performed to reduce the risk of chance, and randomization and stratification are used to minimize the risk of confounding factors. At the same time, broad inclusion criteria are applied to minimize selection and entry bias, and study subjects and event adjudication committees are blinded to treatment in order to avoid information bias [6] . Consistently, contemporary trials aim for the recruitment of large numbers of patients with minimal exclusion criteria to generate robust findings translatable into routine clinical practice.
Overall, these features attest to the internal validity of RCTs, but proved to be not sufficient to ensure the generalizability of their results [17, 18] .
The systematic appraisal of external validity of relevant RCTs could help to identify factors still affecting their effectiveness in representing the real world outside of study protocols.
Significant differences in baseline characteristics and outcomes, for instance, were described for RCT participants and non-participants of the LEADERS and RESO-LUTE III trials, two large ''all-comers'' PCI trials [19] .
Furthermore, marked differences with regard to hospital characteristics between participating and non-participating sites of the recent DAPT trial were reported; a lower cardiovascular disease burden and younger age were also described for participants as compared to non-participants in the trial [20] .
Along the same line, we found that trial participants had a lower risk profile and higher probability of mid-term survival than non-participants. Even though the rationale for non-inclusion of individual subjects had not been prospectively recorded, the important differences in baseline characteristics suggest a tendency to systematically exclude patients with specific features. Female gender continued to be an important determinant of non-participation in the trial. Sex-specific aspects of clinical presentation of CAD and inadequate awareness of the burden of the disease prevent an adequate proportion of women to be enrolled in interventional trials [21] . This underrepresentation hampers our knowledge about the typical aspects of the disease in female compared with male patients and aggravates a gender gap. Several previous reports, indeed, described disparity in the provision of medical care in female population with cardiac diseases [22] [23] [24] .
Advanced age, multiple comorbidities, need for longterm OAC and a more compromised status at presentation also increased the probability to be not included into the trial. These baseline differences translated into worse clinical outcomes of non-participants, especially in the early period after PCI.
All-cause and cardiac death were the stronger determinants of higher risk of the composite endpoints whilst rates of ischemic events (MI and repeat revascularization) were not significantly different between groups.
This finding has two main implications: (1) it reinforces the notion that critically ill patients, with pre-procedural higher probability to die, were preferentially not included in the trial; (2) the widespread use of new generation DES has the potential to mitigate the effects of higher baseline risk profiles on the risk of restenosis.
Indeed, rates of repeat revascularization were higher among registry participants during the early period after PCI (probably driven by higher occurrence of ST), but they were not different between the groups up to 1 year.
As an additional finding, we observed that the imbalance in terms of risk of adverse events between RCT and registry participants was prominent in the setting of ACS. The tendency to enroll lower risk patients was mirrored by a higher proportion of subjects with STEMI and/or cardiogenic shock at time of presentation in the registry. In emergency conditions, patients are less prone or unable to voluntarily accept the participation in studies. Inability to provide informed consent, indeed, was one of the main reasons for exclusion of subjects from two large ''all-comers'' trials and was reported mainly among patients with acute MI [19] . However, other factors hindering the participation in the trials in case of acute MI are still largely unrecognized because of an inadequate use of screening logs.
Overall, our results raise important concerns about the generalizability of current interventional trials: particularly, the persistent underrepresentation of higher risk patients limits our knowledge on how to optimize care among patients at highest risk [15, 25, 26] . A number of tools have been proposed to overcome this issue: simplified acquisition of informed consent to facilitate the enrollment of patients, especially in emergency situations [19] ; use of dedicated checklists inspired to the CONSORT flow diagram [9] ; systematic collection of screening logs [19] ; identification of a dedicated space within journals to report the information about external validity of published RCTs [27] ; embedding of clinical trials in registries [28] . Their implementation in routine clinical practice could help to enhance the relevance of scientific research in several settings.
Our study has the following limitations: (1) although the BIOSCIENCE trial recruited patients at nine hospitals, the present analysis was limited to patients enrolled at a single institution. We acknowledge that considering the experience of a single site disregards the multicenter design of the trial; however, the ability to compare participants with patients included, during the same period, in a dedicated PCI registry with active follow-up and uniform adjudications of adverse events represents a major strength of our work; (2) we did not prospectively record reasons for non-inclusion into the BIOSCIENCE trial precluding an accurate estimate of actual reasons for non-inclusion; (3) selection of registry participants is only one of the numerous categories of external validity; (4) this was a post hoc analysis open to all the limitations of such investigations. Fig. 4 Stratified analyses of POCE at 1-year in pre-specified subgroups. BMI body mass index, BP-SES biodegradable polymersirolimus eluting stent, CAD coronary artery disease, MI myocardial infarction, DP-EES durable polymer-everolimus eluting stent, POCE patient-oriented composite endpoint
Conclusions
Several factors still affect the generalizability of contemporary interventional RCTs. Our study shows important differences between study participants and non-participants with regard to baseline characteristics and clinical outcomes in an unselected patient population referred for PCI. Disparities were not accounted for by study exclusion criteria, and were particularly pronounced among patients presenting with ACS. Major efforts are needed to ensure adequate representativeness of real-world patients and the consequent wide application of the study results.
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